<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00095966</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02629</org_study_id>
    <secondary_id>13169B</secondary_id>
    <secondary_id>CDR0000391850</secondary_id>
    <secondary_id>NCI-6567</secondary_id>
    <secondary_id>UCCRC-13169B</secondary_id>
    <secondary_id>U01CA099118</secondary_id>
    <secondary_id>N01CM62201</secondary_id>
    <nct_id>NCT00095966</nct_id>
  </id_info>
  <brief_title>Sorafenib and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer</brief_title>
  <official_title>A Phase II Study of BAY 43-9006/Gemcitabine for Advanced Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      Sorafenib may stop the growth of tumor cells by stopping blood flow to the tumor and by&#xD;
      blocking the enzymes necessary for their growth. Drugs used in chemotherapy, such as&#xD;
      gemcitabine, work in different ways to stop tumor cells from dividing so they stop growing or&#xD;
      die. Giving sorafenib with gemcitabine may kill more tumor cells. This phase II trial is&#xD;
      studying how well giving sorafenib together with gemcitabine works in treating patients with&#xD;
      locally advanced or metastatic pancreatic cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the objective response rate in patients with locally advanced or metastatic&#xD;
      adenocarcinoma of the pancreas treated with sorafenib and gemcitabine.&#xD;
&#xD;
      II. Determine the toxicity experienced by patients with advanced pancreatic cancer who are&#xD;
      treated with sorafenib plus gemcitabine.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive oral sorafenib twice daily on days 1-28 and gemcitabine IV over 30 minutes&#xD;
      on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 12-35 patients will be accrued for this study within 7 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2004</start_date>
  <primary_completion_date type="Actual">September 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate as measured by RECIST criteria</measure>
    <time_frame>Up to 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>From start of treatment to progression or death, assessed up to 6 months</time_frame>
    <description>Kaplan-Meier curves will be constructed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>At 6 months</time_frame>
    <description>Specific attention will be given to the six-month survival rate, for which 90% confidence intervals will be generated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Kaplan-Meier curves will be constructed</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Adenocarcinoma of the Pancreas</condition>
  <condition>Recurrent Pancreatic Cancer</condition>
  <condition>Stage II Pancreatic Cancer</condition>
  <condition>Stage III Pancreatic Cancer</condition>
  <condition>Stage IV Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment (sorafenib tosylate and gemcitabine hydrochloride)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral sorafenib twice daily on days 1-28 and gemcitabine IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sorafenib tosylate</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Treatment (sorafenib tosylate and gemcitabine hydrochloride)</arm_group_label>
    <other_name>BAY 43-9006</other_name>
    <other_name>BAY 43-9006 Tosylate Salt</other_name>
    <other_name>BAY 54-9085</other_name>
    <other_name>Nexavar</other_name>
    <other_name>SFN</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (sorafenib tosylate and gemcitabine hydrochloride)</arm_group_label>
    <other_name>dFdC</other_name>
    <other_name>difluorodeoxycytidine hydrochloride</other_name>
    <other_name>gemcitabine</other_name>
    <other_name>Gemzar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed adenocarcinoma of the pancreas&#xD;
&#xD;
               -  Locally advanced or metastatic disease&#xD;
&#xD;
                    -  Locally advanced disease must extend outside the boundaries of a standard&#xD;
                       radiotherapy port&#xD;
&#xD;
          -  Not amenable to curative surgery or radiotherapy&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
               -  At least 1 unidimensionally measurable lesion ≥ 20 mm by conventional techniques&#xD;
                  OR ≥ 10 mm by spiral CT scan&#xD;
&#xD;
               -  Pleural effusion and ascites are not considered measurable lesions&#xD;
&#xD;
               -  Outside prior radiotherapy port&#xD;
&#xD;
          -  No known brain metastases&#xD;
&#xD;
          -  Performance status - ECOG 0-1&#xD;
&#xD;
          -  Performance status - Karnofsky 70-100%&#xD;
&#xD;
          -  More than 3 months&#xD;
&#xD;
          -  WBC ≥ 3,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  No evidence of bleeding diathesis&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  AST and/or ALT ≤ 2.5 times upper limit of normal&#xD;
&#xD;
          -  Creatinine normal&#xD;
&#xD;
          -  Creatinine clearance ≥ 60 mL/min&#xD;
&#xD;
          -  No uncontrolled hypertension&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No cardiac arrhythmia&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No active or ongoing infection&#xD;
&#xD;
          -  No other active malignancy&#xD;
&#xD;
          -  No history of allergic reaction attributed to compounds of similar chemical or&#xD;
             biological composition to sorafenib or other study agents&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study compliance&#xD;
&#xD;
          -  No other uncontrolled illness&#xD;
&#xD;
          -  No prior antiangiogenic agents&#xD;
&#xD;
          -  No prior cytotoxic chemotherapy for metastatic disease&#xD;
&#xD;
          -  At least 4 weeks since prior adjuvant chemotherapy (6 weeks for nitrosoureas or&#xD;
             mitomycin) and recovered&#xD;
&#xD;
          -  No prior gemcitabine&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy and recovered&#xD;
&#xD;
          -  No prior investigational drugs&#xD;
&#xD;
          -  No prior sorafenib&#xD;
&#xD;
          -  No prior MAPK signaling agents&#xD;
&#xD;
          -  Concurrent warfarin anticoagulation allowed provided the following criteria are met:&#xD;
&#xD;
               -  Therapeutic on a stable warfarin dose&#xD;
&#xD;
               -  INR ≤ 3&#xD;
&#xD;
               -  Undergo weekly INR testing&#xD;
&#xD;
               -  No active bleeding or pathological condition that carries a high risk of bleeding&#xD;
&#xD;
          -  No concurrent combination antiretroviral therapy for HIV-positive patients&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No other concurrent anticancer therapies&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hedy Kindler</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Chicago Comprehensive Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637-1470</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <study_first_submitted>November 9, 2004</study_first_submitted>
  <study_first_submitted_qc>November 8, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2004</study_first_posted>
  <last_update_submitted>July 1, 2013</last_update_submitted>
  <last_update_submitted_qc>July 1, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 2, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Sorafenib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

